FDA称，如果欣百达获得批准，它将是第一个非传统慢性疼痛止痛药。
If approved, the FDA said Cymbalta would be the first nontraditional analgesic approved for chronic pain.
这项研究针对于用于治疗抑郁症和综合焦虑失调症的度洛西汀或欣百达。
The study looked at the drug duloxetine, or Cymbalta, which is used to treat depression and generalized anxiety disorder.
礼来公司正在向FDA申请将欣百达适应症扩展到慢性疼痛，例如因关节炎导致的膝盖疼痛和腰疼。
Lilly is seeking FDA approval for Cymbalta as a treatment for chronic pain conditions such as knee pain caused by osteoarthritis and lower back pain.
但是FDA还是会允许礼来公司将欣百达作为止痛药在市场上销售。
However, it would allow Lilly to market Cymbalta as a pain treatment.
礼来y公司的临床试验证明，有三分之二的病人在服用欣百达三个月后，腰疼得到缓解。
Two out of three studies Lilly conducted in patients with lower back pain showed the product improved pain relief over about a three-month period.
在服用欣百达或者安慰剂之前，测量每周疼痛指数的平均值，并在研究结束时再次测量。结果表明服用欣百达的一组患者有更明显的改善。
Average weekly pain scores, measured before taking Cymbalta or the placebo and again at the end of the study, showed greater improvement in the Cymbalta group.
在两项研究中，患者服用欣百达后，报告的常见副作用包括恶心、口干、疲劳、腹泻、过量出汗(多汗症)、头晕和便秘。
In both studies, side effects more commonly reported by patients taking Cymbalta included nausea, dry mouth, fatigue, diarrhea, excessive sweating (hyperhidrosis), dizziness, and constipation.
而那项欣百达未能打败安慰剂的研究中，包含更低的20mg欣百达剂量组，以及60 mg欣百达、120 mg欣百达和安慰剂。
The study in which Cymbalta didn't beat the placebo also included a lower (20 milligram) dose of Cymbalta, as well as the 60 milligram dose, 120 milligram dose, and placebo.
分为4个主要部分为45厘米的全长，在3d打印金欣德复制原件和由几百个小零件进行3d打印和组装。
Divided into 4 main parts with a full length of 45 cm, the 3d printed Golden Hind replicates the original and is composed of hundreds of small parts to be 3d printed and assembled.
FDA在1月7日的一份通报中指出，一种欣百达的印刷广告在其主要内容中“完全省去了风险信息”，并将读者引入另一页第一行没有空格的段落里，那里包含的是毫无关系的广告。
The FDA wrote that a print AD for Cymbalta "entirely omits risk information" in the main part of the AD and directs readers to a single-spaced paragraph on another page that included unrelated ads.
FDA在1月7日的一份通报中指出，一种欣百达的印刷广告在其主要内容中“完全省去了风险信息”，并将读者引入另一页第一行没有空格的段落里，那里包含的是毫无关系的广告。
The FDA wrote that a print AD for Cymbalta "entirely omits risk information" in the main part of the AD and directs readers to a single-spaced paragraph on another page that included unrelated ads.
应用推荐